183 related articles for article (PubMed ID: 35003893)
21. Linking Binary Gene Relationships to Drivers of Renal Cell Carcinoma Reveals Convergent Function in Alternate Tumor Progression Paths.
Poehlman WL; Hsieh JJ; Feltus FA
Sci Rep; 2019 Feb; 9(1):2899. PubMed ID: 30814637
[TBL] [Abstract][Full Text] [Related]
22. Somatic mutations in renal cell carcinomas from Chinese patients revealed by whole exome sequencing.
Wang J; Xi Z; Xi J; Zhang H; Li J; Xia Y; Yi Y
Cancer Cell Int; 2018; 18():159. PubMed ID: 30349421
[TBL] [Abstract][Full Text] [Related]
23. Phenotype analysis of tumour-infiltrating lymphocytes and lymphocytes in peripheral blood in patients with renal carcinoma.
Kopecký O; Lukesová S; Vroblová V; Vokurková D; Morávek P; Safránek H; Hlávková D; Soucek P
Acta Medica (Hradec Kralove); 2007; 50(3):207-12. PubMed ID: 18254275
[TBL] [Abstract][Full Text] [Related]
24. Identification of an enriched CD4+ CD8alpha++ CD8beta+ T-cell subset among tumor-infiltrating lymphocytes in human renal cell carcinoma.
Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Dal Cin P; Van den Berghe H; Ceuppens JL
Int J Cancer; 1997 Apr; 71(2):178-82. PubMed ID: 9139839
[TBL] [Abstract][Full Text] [Related]
25. T cell functions of IL-2-activated tumor-infiltrating lymphocytes from renal cell carcinoma.
Morita T; Salmeron MA; Hayakawa K; Swanson DA; von Eschenbach AC; Itoh K
Reg Immunol; 1992; 4(4):225-35. PubMed ID: 1476875
[TBL] [Abstract][Full Text] [Related]
26. Immune signature of tumor infiltrating immune cells in renal cancer.
Geissler K; Fornara P; Lautenschläger C; Holzhausen HJ; Seliger B; Riemann D
Oncoimmunology; 2015 Jan; 4(1):e985082. PubMed ID: 25949868
[TBL] [Abstract][Full Text] [Related]
27. Mutations in renal cell carcinoma.
D'Avella C; Abbosh P; Pal SK; Geynisman DM
Urol Oncol; 2020 Oct; 38(10):763-773. PubMed ID: 30478013
[TBL] [Abstract][Full Text] [Related]
28. PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection.
MacFarlane AW; Jillab M; Plimack ER; Hudes GR; Uzzo RG; Litwin S; Dulaimi E; Al-Saleem T; Campbell KS
Cancer Immunol Res; 2014 Apr; 2(4):320-31. PubMed ID: 24764579
[TBL] [Abstract][Full Text] [Related]
29. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma.
Bukur J; Rebmann V; Grosse-Wilde H; Luboldt H; Ruebben H; Drexler I; Sutter G; Huber C; Seliger B
Cancer Res; 2003 Jul; 63(14):4107-11. PubMed ID: 12874014
[TBL] [Abstract][Full Text] [Related]
30. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
31. [Monitoring of anti-tumour cell-mediated response in patients with renal cell carcinoma, disturbance of T cell proliferation].
Lukesová S; Vroblová V; Hlávková D; Kopecký O; Vokurková D; Morávek P; Safránek H; Soucek P
Vnitr Lek; 2008 Feb; 54(2):139-45. PubMed ID: 23687704
[TBL] [Abstract][Full Text] [Related]
32. Tumor and immune remodeling following radiotherapy in human renal cell carcinoma.
Chow J; Khan A; Gaudieri M; Wasik BJ; Conway A; Soh KT; Repasky EA; Schwaab T; Wallace PK; Abrams SI; Singh AK; Muhitch JB
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37080610
[TBL] [Abstract][Full Text] [Related]
33. Human renal-cell carcinoma cells are able to activate natural killer cells.
Hayakawa K; Morita T; Augustus LB; von Eschenbach AC; Itoh K
Int J Cancer; 1992 May; 51(2):290-5. PubMed ID: 1533204
[TBL] [Abstract][Full Text] [Related]
34. PBRM1 and VHL expression correlate in human clear cell renal cell carcinoma with differential association with patient's overall survival.
Högner A; Krause H; Jandrig B; Kasim M; Fuller TF; Schostak M; Erbersdobler A; Patzak A; Kilic E
Urol Oncol; 2018 Mar; 36(3):94.e1-94.e14. PubMed ID: 29169846
[TBL] [Abstract][Full Text] [Related]
35. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P
Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
[TBL] [Abstract][Full Text] [Related]
36. Characterization of the expression and immunological impact of the transcriptional activator CREB in renal cell carcinoma.
Friedrich M; Stoehr C; Jasinski-Bergner S; Hartmann A; Wach S; Wullich B; Steven A; Seliger B
J Transl Med; 2020 Sep; 18(1):371. PubMed ID: 32993793
[TBL] [Abstract][Full Text] [Related]
37. Obesity diminishes response to PD-1-based immunotherapies in renal cancer.
Boi SK; Orlandella RM; Gibson JT; Turbitt WJ; Wald G; Thomas L; Buchta Rosean C; Norris KE; Bing M; Bertrand L; Gross BP; Makkouk A; Starenki D; Farag KI; Sorge RE; Brown JA; Gordetsky J; Yasin H; Garje R; Nandagopal L; Weiner GJ; Lubaroff DM; Arend RC; Li P; Zakharia Y; Yang E; Salem AK; Nepple K; Marquez-Lago TT; Norian LA
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33427691
[TBL] [Abstract][Full Text] [Related]
38. PBRM1 and BAP1 as novel targets for renal cell carcinoma.
Brugarolas J
Cancer J; 2013; 19(4):324-32. PubMed ID: 23867514
[TBL] [Abstract][Full Text] [Related]
39. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma.
Thompson RH; Dong H; Lohse CM; Leibovich BC; Blute ML; Cheville JC; Kwon ED
Clin Cancer Res; 2007 Mar; 13(6):1757-61. PubMed ID: 17363529
[TBL] [Abstract][Full Text] [Related]
40. Multiplexed single-cell pathology reveals the association of CD8 T-cell heterogeneity with prognostic outcomes in renal cell carcinoma.
Murakami T; Tanaka N; Takamatsu K; Hakozaki K; Fukumoto K; Masuda T; Mikami S; Shinojima T; Kakimi K; Tsunoda T; Sawada K; Imamura T; Mizuno R; Oya M
Cancer Immunol Immunother; 2021 Oct; 70(10):3001-3013. PubMed ID: 34259900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
